SAVIMS

SAVIMS logo white
Menu

Other scientific evidence

Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

FDA-Approved Prescription Drugs Withdrawn for Safety Reasons

| | Ethics, Excess deaths, Other scientific evidence, Reference Library, Resource Type, Statistical evidence, Vaccine safety & adverse events, Vaccines

Reference: ProCon.org. (2021). FDA-approved prescription drugs later pulled from the market by the FDA. Retrieved from https://prescriptiondrugs.procon.org/fda-approved-prescription-drugs-later-pulled-from-the-market/ Summary: The article by ProCon.org discusses various prescription drugs that were once FDA-approved but later withdrawn from the market due to safety concerns. The FDA’s role in drug removal is highlighted, emphasising that drugs are typically pulled when […]

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Quarterly Update on COVID-19 Adverse Events of Special Interest

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Law, B. (2020). Priority List of COVID-19 Adverse Events of Special Interest: Quarterly Update December 2020. Safety Platform for Emergency Vaccines (SPEAC). Summary: The report provides a quarterly update on the Safety Platform for Emergency Vaccines (SPEAC) regarding Adverse Events of Special Interest (AESI) related to COVID-19. The December 2020 update includes three new

COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Prophylaxis and Early Treatment of COVID-19: The I-MASK+ Protocol

| | COVID-19, Ivermectin, Nutritional supplements, Other repurposed substances, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: FLCCC Alliance. (2021). I-MASK+ prophylaxis & early outpatient treatment protocol for COVID-19. Retrieved from www.flccc.net Summary: The FLCCC Alliance’s I-MASK+ protocol provides guidelines for the prophylaxis and early outpatient treatment of COVID-19. It recommends the use of Ivermectin, along with Vitamin D3, Vitamin C, Quercetin, Zinc, Melatonin, and Aspirin for high-risk individuals and post-exposure

COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID Vaccine Safety Concerns: An Analysis

| | COVID-19, Covid-19 vaccines, Excess deaths, Other scientific evidence, Resource Type, Statistical evidence, Vaccine risk benefit analysis, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Kirsch, S. (2021). All you need to know about COVID vaccine safety. COVID-19 Early Treatment Fund. Summary: Steve Kirsch, Executive Director of the COVID-19 Early Treatment Fund, argues that COVID vaccines may be responsible for more deaths than they prevent. He estimates over 150,000 excess deaths associated with the vaccines, contrasting this figure with

COVID-19, Other scientific evidence, Resource Type, Viral illnesses

FDA Guidance on Antibody Testing for COVID-19 Immunity

| | COVID-19, Other scientific evidence, Resource Type, Viral illnesses

Reference: U.S. Food and Drug Administration. (2021, May 19). Antibody testing is not currently recommended to assess immunity after COVID-19 vaccination: FDA safety communication. https://www.fda.gov/medical-devices/safety-communications/antibody-testing-not-currently-recommended-assess-immunity-after-covid-19-vaccination. Summary: The FDA has issued a warning that antibody tests for SARS-CoV-2 should not be used to determine immunity following COVID-19 vaccination. While these tests can indicate previous infection, they

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

V-Safe Data Insights – ICAN

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Informed Consent Action Network. (2022). V-safe data. https://icandecide.org/v-safe-data/#v-safe-downloads Summary: The V-Safe Data report from the Informed Consent Action Network (ICAN) presents comprehensive statistics on adverse health impacts following COVID-19 vaccinations. The data indicates that over 10 million individuals registered on the V-Safe platform, with significant health impacts reported, totalling approximately 6.4 million. The report

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

Controversial Call to Halt COVID-19 Vaccinations

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Treatment, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Bruno, R., McCullough, P., et al. (2021). 157 Top Scientists and Doctors Release Shocking Study on COVID Vaccines and Demand Immediate Stop to All Vaccinations. Global Research. Summary: A report by 57 prominent scientists and doctors has raised significant concerns about the safety and efficacy of COVID-19 vaccines, urging an immediate cessation of vaccination

COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

COVID-19 Adverse Events of Special Interest: December 2020 Update

| | COVID-19, Covid-19 vaccines, Other scientific evidence, Resource Type, Vaccine safety & adverse events, Vaccines, Viral illnesses

Reference: Law, B. (2020). Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020. Safety Platform for Emergency Vaccines. Summary: The report updates the list of adverse events of special interest AESI) associated with COVID-19 vaccines, generated by the Safety Platform for Emergency Vaccines (SPEAC) Project. The quarterly review focuses on new

COVID-19, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Evaluation of Remdesivir for COVID-19: Evidence Review

| | COVID-19, Other scientific evidence, Resource Type, Treatment, Viral illnesses

Reference: McGee, S., & De Waal, R. (2020). Rapid review of remdesivir for COVID-19: Update 15 December 2020. South African National Department of Health. Summary: The South African National Department of Health conducted a rapid review of remdesivir’s efficacy for treating hospitalised COVID-19 patients. The analysis included five randomised controlled trials (RCTs) with over 7,700

Scroll to Top